Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Securities Claims Against Pacira Pharmaceuticals, Inc.

NEW YORK, Sept. 29, 2014 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company") (NasdaqGS: PCRX).  Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at [email protected] or 212-697-6484.

The investigation focuses on whether the Company and certain of its executives violated federal securities laws.

On September 25, 2014, shares of Pacira fell 4.70 or 4.42% during intraday trading to trade at $101.58 after the Company announced that it received a Warning Letter from the U.S. Food and Drug Administration's ("FDA") Office of Prescription Drug Promotion referencing certain promotional materials for EXPAREL^® (bupivacaine liposome injectable suspension), an injectable drug that numbs post-surgical pain.

In the letter, the FDA said Pacira promotes its drug EXPAREL as being able to work for up to 72 hours when it has only been approved for 24-hour pain relief.  "These claims overstate Exparel's efficacy and are misleading," the FDA said in the letter. 

If you are aware of any facts relating to this investigation, or purchased shares of Pacira, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected].  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
[email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED